Drugs / cAd3-Sudan
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06803342 Comparator | Jun 2025 → Feb 2027 expected | Ebola hemorrhagic fever | Albert B. Sabin Vaccine Institute | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cAd3-Sudan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06803342 ↗ |
| Known as | cAd3-Sudan Vaccine | “Single dose of cAd3-Sudan Vaccine (1x10^11 PU) administered intramuscularly (IM) with needle and syringe in a volume of 0.83 mL.” NCT06803342 ↗ |
| Modality | Vaccine | “Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Virus Vaccine” NCT06803342 ↗ |
| Route | Intramuscular | “administered intramuscularly (IM)” NCT06803342 ↗ |